glp 1 m Frontiers backed formula powered by dihydroberberine—known as “Nature’s GLP The GLP-1 Agonist Boom in

Disclosures: Grahame Evans: Nothing to Disclose, Xinruo Zhang: Nothing to Disclose, Jennifer Below: Nothing to Disclose, Kari North: Nothing to Disclose, May Hagiwara: Takeda pharmaceuticals: Employee, Chitra Karki: Takeda Development Center Americas, Inc.: Employee, Takeda Development Center Americas, Inc.: Stock - publicly traded company, Tami Nussbaum: Takeda: Employee, Suna Park: Takeda Pharmaceuticals: Employee, Kaili Ren: Nothing to Disclose, Virginia Clark: Nothing to Disclose 2525 DISEASE PROGRESSION IN ADULT PATIENTS WITH ALPHA-1 ANTITRYPSIN DEFICIENCY-ASSOCIATED LIVER CIRRHOSIS: A RETROSPECTIVE COHORT STUDY OF THE US VETERANS AFFAIRS HEALTH DATABASE Dustin Bastaich 1 Bassam Dahman 1 Suna Park 2 May Hagiwara 2 Chitra Karki 2 Tami Nussbaum 2 Raphaella Ferreira 3 Austen Hentschel 4 David Kaplan 5 Andres Samos 4 Binu John 6 , 1 Virginia Commonwealth University, 2 Takeda Development Center Americas, Inc., 3 Larkin Community Hospital, 4 Florida International University, 5 University of Pennsylvania, 6 University of Miami Background: Alpha-1 antitrypsin deficiency (AATD) may manifest as liver and/or lung disease with a variably progressive course

We never recommend a product or service unless it meets our editorial standards

She helps these patients cope and adjust to the psychological, behavioral, and cognitive changes that occur as they prepare for bariatric surgery, during recovery, and in the months following surgery

Discontinuation should be considered if nausea persists despite dose adjustments and supportive measures